PRESS RELEASE published on 07/17/2025 at 15:00, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 1 year 3 months ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 1 year 3 months ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 1 year 3 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 1 year 4 months ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
PRESS RELEASE published on 07/01/2025 at 08:54, 1 year 4 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics successfully completes private placement of nearly EUR 4 million, attracting new international investors. Funds to advance gene therapies for retinal diseases and CNS disorders Private Placement GenSight Biologics Gene Therapies Retinal Diseases CNS Disorders
BRIEF published on 06/26/2025 at 07:35, 1 year 4 months ago GenSight Biologics: Advances in Manufacturing Partnership with Catalent Gene Therapy GenSight Biologics LUMEVOQ® NOHL Catalent
PRESS RELEASE published on 06/26/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
BRIEF published on 05/13/2025 at 22:05, 1 year 5 months ago GenSight Biologics Shareholders Approve Majority of Board's Resolutions Shareholder Meeting Board Resolutions GenSight Biologics LUMEVOQ® Phase III RECOVER
PRESS RELEASE published on 05/13/2025 at 22:00, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics announces approval of all resolutions at Combined General Meeting on May 13, 2025. Company highlights achievements of 2024 and strategic priorities for 2025 Strategic Priorities Approval Combined General Meeting GenSight Biologics Achievements
Published on 10/30/2026 at 23:35, 1 day 17 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 17 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 21 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 1 hour ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 6 hours 8 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 11 hours 43 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 17 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 4 hours ago Capital increase through exercise of subscription rights
